当前位置:首页 >财报库 > 报告详情

罗氏Roche Holdings(RHHBY)2024年业绩演示与未来展望报告(含附录)「OTC」(英文版)(189页).pdf

上传人: Kell****reet 编号:652455 2025-05-14 189页 3.78MB

下载:

1、This presentation contains certain forward-looking statements.These forward-looking statements may be identified by words such as believes,expects,anticipates,projects,intends,should,seeks,estimates,future or similar expressions or by discussion of,among other things,strategy,goals,plans or intentio

2、ns.Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation,among others:1pricing and product initiatives of competitors;2legislative and regulatory developments and economic conditions;3 delay or in

3、ability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery,development or marketing of new products or new uses of existing products,including without limitation negative

4、results of clinical trials or research projects,unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 litigation;10 loss of key executives

5、 or other employees;and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the histo

6、rical published earnings or earnings per share of Roche.For marketed products discussed in this presentation,please see full prescribing information on our website All mentioned trademarks are legally protected.Roche2024 resultsBasel,30 January 2025GroupThomas SchineckerChief Executive Officer Perfo

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了罗氏集团2024年的业绩报告。报告指出,罗氏集团在2024年实现了7%的销售增长,核心EPS增长7%(不包括2023年税务纠纷解决的影响)。在制药和诊断两大业务部门中,均实现了持续强劲的增长。其中,制药部门实现了9%的销售增长,诊断部门实现了8%的销售增长。此外,报告还强调了罗氏集团在研发方面的投入,以及未来增长潜力。
2024年罗氏集团业绩如何? 罗氏制药有哪些新产品上市? 罗氏诊断有哪些新产品发布?
客服
商务合作
小程序
服务号
折叠